Plozasiran: Groundbreaking RNA Interference Agent Targets APOC3 for Mixed Hyperlipidemia suggests research Medha Baranwal5 Jun 2024 10:00 AM ISTUSA: In a groundbreaking development in lipid management, researchers have unveiled a promising RNA interference (RNAi) agent known as Plozasiran....
Hypertension: KARDIA-1 trial suggests zilebesiran potentially effective antihypertensive with quarterly or biannual dosing Medha Baranwal21 Feb 2024 7:15 PM ISTUSA: RNA interference with zilebesiran can significantly lower blood pressure for up to 6 months, indicating potential for use as an effective...
